N/A
N=228
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer
Peptic Ulcer
Bottom Line
View on ClinicalTrials.gov: NCT02418312 ↗Enrolled (actual)
228
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcome: Primary: Number of Participants With Healed Peptic Ulcer — 106; 101 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- histamine-2 receptor antagonist (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Kaohsiung Veterans General Hospital.
- Primary completion
- Oct 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Healed Peptic Ulcer |
106; 101 | — |
Summary
Whether H2 receptor antagonist can prevent thienopyridine-related peptic ulcer remains unclear.
Eligibility Criteria
Inclusion Criteria
- The past history of gastroduodenal ulcer and underwent endoscopy for dyspeptic symptoms.
- thienopyridine users without baseline gastroduodenal ulcer at initial endoscopy.
- They are adult patients aged least 20 years of age.
Exclusion Criteria
- They have a history of gastric or duodenal surgery other than oversewing of a perforation.
- They require long-term treatment with non-steroidal anti-inflammatory drugs.
- serious disease.
Data sourced from ClinicalTrials.gov (NCT02418312). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.